Ribonucleotide reductase inhibitors and future drug design

J. Shao, B. Zhou, Bernard Chu, Y. Yen

Research output: Contribution to journalArticle

  • 184 Citations

Abstract

Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery. © 2006 Bentham Science Publishers Ltd.

Original languageEnglish
Pages (from-to)409-431
Number of pages23
JournalCurrent Cancer Drug Targets
Volume6
Issue number5
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Drug Design
Neoplasms
Clinical Trials
Deoxyribonucleotides
Ribonucleotides
Translational Medical Research
DNA Replication
DNA Repair
Carcinogenesis
Drug Therapy
DNA
Enzymes

Keywords

  • Classification
  • Clinical trial and application
  • Drug discovery
  • Inhibitors
  • Mechanism of action
  • Ribonucleotide reductase
  • Structure and function

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Ribonucleotide reductase inhibitors and future drug design. / Shao, J.; Zhou, B.; Chu, Bernard; Yen, Y.

In: Current Cancer Drug Targets, Vol. 6, No. 5, 2006, p. 409-431.

Research output: Contribution to journalArticle

Shao, J.; Zhou, B.; Chu, Bernard; Yen, Y. / Ribonucleotide reductase inhibitors and future drug design.

In: Current Cancer Drug Targets, Vol. 6, No. 5, 2006, p. 409-431.

Research output: Contribution to journalArticle

@article{69a0098e83ce47e29c8c2b45b988af43,
title = "Ribonucleotide reductase inhibitors and future drug design",
abstract = "Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery. © 2006 Bentham Science Publishers Ltd.",
keywords = "Classification, Clinical trial and application, Drug discovery, Inhibitors, Mechanism of action, Ribonucleotide reductase, Structure and function",
author = "J. Shao and B. Zhou and Bernard Chu and Y. Yen",
year = "2006",
doi = "10.2174/156800906777723949",
volume = "6",
pages = "409--431",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Ribonucleotide reductase inhibitors and future drug design

AU - Shao,J.

AU - Zhou,B.

AU - Chu,Bernard

AU - Yen,Y.

PY - 2006

Y1 - 2006

N2 - Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery. © 2006 Bentham Science Publishers Ltd.

AB - Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery. © 2006 Bentham Science Publishers Ltd.

KW - Classification

KW - Clinical trial and application

KW - Drug discovery

KW - Inhibitors

KW - Mechanism of action

KW - Ribonucleotide reductase

KW - Structure and function

UR - http://www.scopus.com/inward/record.url?scp=33745823841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745823841&partnerID=8YFLogxK

U2 - 10.2174/156800906777723949

DO - 10.2174/156800906777723949

M3 - Article

VL - 6

SP - 409

EP - 431

JO - Current Cancer Drug Targets

T2 - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 5

ER -